The Target Therapy segment is expected to show the highest CAGR of 9.68% during the forecast period. The target therapy includes hormone therapies, gene expression modulators, apoptosis inducers, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells, while sparing the toxicity to off-target cells. According to the global cancer therapy market it was valued at USD 136,254.35 million in 2018, and is estimated to be valued at USD 220, 701.26 million in 2024, witnessing a CAGR of 8.37%. The market growth has been driven by certain factors that include increasing Patient Assistance Programs (PAPs), increasing government initiatives from key players.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
